ArticlePediatric dermatology
Regorafenib-Induced Hand-Foot Skin Reaction in an Adolescent.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Toxic Epidermal Necrolysis in a Patient with Hepatocellular Carcinoma Receiving Pembrolizumab Plus Regorafenib: A Case Report.Cancer management and research · 2026Article
- Regorafenib-Induced Hand-Foot Skin Reaction in an Adolescent.Pediatric dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regorafenib is a multikinase inhibitor commonly used in the management of hepatocellular carcinoma, gastrointestinal stromal tumors (GIST), and colorectal cancer. It is also used off-label for progressive or metastatic osteosarcoma, which is the most common primary bone malignancy in children and adolescents. While hand-foot skin reaction (HFSR) is a well-documented side effect associated with regorafenib use, no standard guidelines currently exist for preventing and managing regorafenib-associated HFSR in children, or for HFSR and hand-foot syndrome related to other chemotherapy agents. We present a case of regorafenib-induced HFSR in an adolescent with metastatic osteosarcoma that highlights an effective dose-reduction regimen and treatment plan that ultimately resolved her grade 3 HFSR and allowed her to resume alternate anticancer treatment immediately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.